MRNS MARINUS PHARMACEUTICALS INC

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

RADNOR, Pa.--(BUSINESS WIRE)--

, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results.

Tuesday, August 13, 8:30 a.m. E.T.

Domestic: (877) 405-1242

International: (201) 389-0852

Webcast Registration:

An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at .

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022. For more information about Marinus visit .

EN
30/07/2024

Underlying

MRNSMARINUS PHARMACEUTICALS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MARINUS PHARMACEUTICALS INC

 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals Provides Business Update and Reports Third Qua...

RADNOR, Pa.--(BUSINESS WIRE)-- , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. “We are pleased to see continued commercial growth of ZTALMY with more than 200 patients active on therapy and a steady increase in demand,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. “In 2024, our Phase 3 data in status epilepticus and tuberous sclerosis complex showed meaningful clinical acti...

November 12, 2024 1 EN
 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTS...

RADNOR, Pa.--(BUSINESS WIRE)-- , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency. While reductions in seizure frequency favored the ganaxolone arm, the primary endpoint did not achieve statistical significance. “As the first controlled trial in ...

October 24, 2024 1 EN
 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RA...

RADNOR, Pa.--(BUSINESS WIRE)-- , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting. Topline data demonstrating that the trial met one of two co-primary endpoints were reported in June 2024. In the RAISE trial (), patients with RSE that failed at least two antiseizure medications were randomized to IV gana...

October 17, 2024 1 EN
 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals Further Strengthens Intellectual Property Esta...

RADNOR, Pa.--(BUSINESS WIRE)-- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has added to its intellectual property (IP) estate with a new patent issued by the United States Patent and Trademark Office (USPTO) for ZTALMY® (ganaxolone) oral titration regimens covering the treatment of a range of epilepsy disorders, including CDKL5 deficiency disorder, tuberous sclerosis complex (TSC) and Lennox-Gastaut syndrome (LGS). The U.S. patent No. 12,115,169 expires in September 2042. “The new patent grant...

October 15, 2024 1 EN
 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals Announces Podium and Poster Presentations at t...

RADNOR, Pa.--(BUSINESS WIRE)-- , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that additional data from the Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data from patients with status epilepticus will be presented at the upcoming Neurocritical Care Society (NCS) 22nd Annual Meeting, being held October 14-17 in San Diego, California. Presentation details are as follows: Podium Presentation Details: Thursday, October 17, 2024, 9:35-9:55 a.m. PT Title: E...

October 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch